Exelixis, Inc. (NASDAQ:EXEL) CEO Michael Morrissey sold 34,721 shares of the firm’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $21.37, for a total transaction of $741,987.77. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Michael Morrissey also recently made the following trade(s):
- On Wednesday, July 3rd, Michael Morrissey sold 34,721 shares of Exelixis stock. The stock was sold at an average price of $21.03, for a total transaction of $730,182.63.
- On Wednesday, May 8th, Michael Morrissey sold 42,000 shares of Exelixis stock. The stock was sold at an average price of $20.15, for a total transaction of $846,300.00.
- On Wednesday, April 24th, Michael Morrissey sold 40,000 shares of Exelixis stock. The stock was sold at an average price of $20.75, for a total transaction of $830,000.00.
NASDAQ:EXEL opened at $21.27 on Monday. The firm has a fifty day moving average price of $20.76. Exelixis, Inc. has a 1-year low of $13.42 and a 1-year high of $25.31. The company has a current ratio of 7.56, a quick ratio of 7.48 and a debt-to-equity ratio of 0.01. The stock has a market cap of $6.42 billion, a price-to-earnings ratio of 14.87, a price-to-earnings-growth ratio of 0.48 and a beta of 1.93.
Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.24 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.24. Exelixis had a net margin of 75.97% and a return on equity of 37.21%. The firm had revenue of $215.49 million for the quarter, compared to analyst estimates of $206.06 million. During the same period last year, the firm posted $0.40 EPS. Exelixis’s quarterly revenue was up .8% on a year-over-year basis. As a group, equities research analysts anticipate that Exelixis, Inc. will post 0.96 earnings per share for the current year.
A number of equities analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Great Portland Estates from a “hold” rating to a “sell” rating in a research report on Tuesday, April 16th. Cowen restated a “buy” rating on shares of Avrobio in a research report on Monday, July 15th. Morgan Stanley raised their target price on shares of Zynga and gave the stock an “overweight” rating in a research report on Thursday, May 2nd. ValuEngine lowered shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 17th. Finally, BidaskClub lowered shares of Westport Fuel Systems from a “buy” rating to a “hold” rating in a research report on Friday. Six research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Exelixis has a consensus rating of “Buy” and a consensus target price of $28.38.
A number of large investors have recently bought and sold shares of EXEL. Icon Wealth Partners LLC purchased a new position in Exelixis in the 1st quarter valued at $27,000. Bessemer Group Inc. purchased a new stake in shares of Exelixis during the 2nd quarter worth $28,000. Cornerstone Advisors Inc. boosted its position in shares of Exelixis by 26.5% during the 1st quarter. Cornerstone Advisors Inc. now owns 2,413 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 505 shares in the last quarter. Rehmann Capital Advisory Group boosted its position in shares of Exelixis by 231.3% during the 1st quarter. Rehmann Capital Advisory Group now owns 2,438 shares of the biotechnology company’s stock worth $58,000 after purchasing an additional 1,702 shares in the last quarter. Finally, FinTrust Capital Advisors LLC boosted its position in shares of Exelixis by 124.0% during the 1st quarter. FinTrust Capital Advisors LLC now owns 2,533 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 1,402 shares in the last quarter. Hedge funds and other institutional investors own 78.22% of the company’s stock.
Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
Featured Article: Dividend
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.